13 minutes agoStudy of The Lancet: The third dose of anti vaccine CO VID is not necessary
Periskopi(5 years ago)
(5 years ago)A third strengthening dose for general population is not required because vaccines against COVID-19 are very effective in preventing serious diseases, according to a report published by The Lancet on Monday. Some countries have begun offering additional doses because of fear of the much more contagious Delta version, making [...]
Some countries have begun to offer additional doses due to fears for the Delta variant much more contagious, causing the World Health Organization (OBSH) to seek a mortorium for third doses amid concerns about vaccine supplies to poorer countries where millions have not yet received the first dose.
But a report from scientists, including O The BSH concluded that even with the Delta threat, “strengthenings for the general population are not appropriate at this stage of pandemic”, Telegrafi conveys.
The authors, who revised observational studies and clinical trials, found that vaccines remain very effective against the serious symptoms of COVID-19, in all major versions of the virus, including Delta, even though they had lower success in preventing astropical diseases.
Overall, the currently available studies do not provide reliable evidence of the significant decline in protection against serious diseases, which is the main purpose of the vaccine”, said lead author Ana-Maria Henao-Restrepo of WHO.
She said the doses of the vaccine should take priority for people worldwide who still expect a dose.
“If vaccines were placed where they would do their best, they could hasten the end of the pandemic by preventing further evolution of”, she added.
France has begun to deliver third doses to the elderly and people with compromised immune systems, while Israel has gone further, offering children 12 and older a third dose five months after full inoculation.
Lancet's research concluded that current variants had not developed enough to save the immune response provided by vaccines currently in use.
The authors argue that if new mutations of the virus that were able to avoid this response appeared, it would be better to provide incentives of specially modified vaccines aimed at newer variants than those based on existing vaccines.
Meanwhile, WHO chief Tedros Adhanom Ghebrreesus has called on countries to avoid giving up additional doses by year's end.
The United Nations health agency has set a global goal of seeing each country vaccinate at least 10% of its population by the end of this month, and at least 40% by the end of this year.
